Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock - CYCCP STOCK NEWS

Cyclacel Pharmaceuticals announced the dosing of the first patient in a Phase 1/2 trial for fadraciclib, a next-generation CDK2/9 inhibitor, targeting advanced solid tumors and lymphomas. This study marks a significant milestone in their clinical development program, which aims to establish fadraciclib's safety and efficacy across various cancer types, including breast and endometrial cancers. With promising preclinical data indicating substantial tumor reduction in some patients, Cyclacel anticipates further trials and potential regulatory submissions in the near future.

Cyclacel Pharmaceuticals announced its participation in the Ladenburg Thalmann’s Virtual 2021 Healthcare Conference set for July 13-14, 2021. Spiro Rombotis, President & CEO, will present Cyclacel’s business overview and engage in an analyst-led fireside chat.

Presentation details:

• Date: July 14, 2021
• Time: 10:30-10:55 am EDT
• Location: Virtual; Track 1

The archived webcast will be available on Cyclacel's website for 90 days following the event.

Cyclacel Pharmaceuticals (NASDAQ: CYCC, CYCCP) announced FDA authorization for its IND application of oral fadraciclib, a CDK2/9 inhibitor targeting solid tumors. The Phase 1b/2 trial will focus on various cancers, including KRAS mutant types. The company reported $47.8 million in cash as of March 31, 2021, an increase from $33.4 million at year-end 2020, thanks to a recent equity financing of $13.5 million. Cyclacel aims to initiate multiple clinical studies in 2021, leveraging recent research supporting fadraciclib's efficacy against KRAS-mutated cancers.

Cyclacel Pharmaceuticals (NASDAQ: CYCC, CYCCP) will release its first quarter financial results on May 12, 2021, followed by a conference call at 4:30 p.m. EDT. The company focuses on developing innovative cancer medicines, including fadraciclib and CYC140. These therapies target cancer biology through cell cycle and transcriptional regulation. Cyclacel's ongoing strategy aims to establish a diverse biopharmaceutical business centered on oncology and hematology.

Cyclacel Pharmaceuticals (NASDAQ: CYCC, CYCCP) has successfully closed its underwritten public offering of 2,078,214 shares at $7.00 per share, raising approximately $14.5 million in gross proceeds. The offering included the full exercise of the underwriter's over-allotment option. Funds will be utilized for growth strategies, working capital, and R&D expenses. The offering was conducted under an effective shelf registration statement by the SEC. Oppenheimer & Co. Inc. served as the sole book-running manager for this public offering.

Cyclacel Pharmaceuticals will present at the Oppenheimer 31st Annual Healthcare Conference on March 18, 2021, at 9:20 AM (EDT). CEO Spiro Rombotis will discuss the company's progress and key programs. Investors can attend one-on-one meetings during this virtual event.

A live webcast will be available on Cyclacel's website and archived for 90 days. The company specializes in developing innovative cancer treatments, focusing on a pipeline that includes fadraciclib and CYC140.

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, CYCCP) announced a public offering of 1,807,143 shares of common stock at $7.00 per share, with gross proceeds anticipated to be approximately $12.65 million before expenses. The offering will close around March 16, 2021, pending customary conditions. Cyclacel plans to use the net proceeds for growth strategies, working capital, and R&D. Oppenheimer & Co. Inc. leads the offering, with additional co-managers involved. The offering is conducted under an effective shelf registration with the SEC.

Cyclacel Pharmaceuticals (NASDAQ: CYCC, CYCCP) announced a proposed underwritten public offering of its common stock, which includes a 30-day option for underwriters to purchase an additional 15% of shares. The exact size and terms of the offering remain uncertain and depend on market conditions. Cyclacel plans to utilize net proceeds from this offering for general corporate purposes, including research and development expenses. Oppenheimer & Co. Inc. serves as the sole book-running manager for the offering, registered under Form S-3 with the SEC.

Cyclacel Pharmaceuticals reported financial results for Q4 and the full year 2020, with a net loss of $6.6 million for the quarter and $12.4 million for the year. Cash and cash equivalents stood at $33.4 million as of December 31, 2020, with additional proceeds of $4.3 million from warrant exercises post-year-end. The company announced plans to advance clinical studies of fadraciclib and CYC140 in various cancer types. Significant milestones for 2021 include the initiation of multiple Phase 1b/2 studies and the expected continuation of cash resources through early 2023.